Assessing response to treatment using imaging with PET/MRI in advanced renal cancer

INTERVENTION: Participants with metastatic renal cell cancer will undergo FDG PET/MRI scans at baseline, 12 and 24 weeks following the start of their standard treatment and results compared to the routine clinical CT scans at these time‐points. Each PET/MRI will take approximately one hour. The imaging intervention is over 24 weeks and the imaging follow up period extends to the 36 week clinical CT scan. Subsequent consensus panel assessment of clinical and all imaging data up to 36‐weeks will confirm disease status. CONDITION: Specialty: Cancer, Primary sub‐specialty: Renal; UKCRC code/ Disease: Cancer/ Malignant neoplasms of urinary tract ; Cancer ; Renal cell cancer PRIMARY OUTCOME: disease response or non‐response measured by PET/MRI and CT at 12 and 24 weeks and clinical examination and CT at 36 weeks. SECONDARY OUTCOME: Time to progression will be measured by clinical examination and CT at standard three to six monthly follow up clinic visits. INCLUSION CRITERIA: 1. Adult patients (male or female > 18 years old) with metastatic renal cell carcinoma 2. Metastases with =1 measurable sites, =2cm, planned for targeted therapy 3. ECOG performance status 0‐2